Lupin Limited — PPTs, 12-02-2025: Investor Presentation

**Financial Highlights:** Lupin reported robust Q3 FY25 performance with net sales of ₹56,186 mn, a 10.6% year-on-year increase. EBITDA stood at ₹13,659 mn, reflecting a significant rise of 33.7% YoY, resulting in an EBITDA margin of 24.3%. Net income surged to ₹8,552 mn, marking a 39.5% increase compared to the previous year.

**Strategic Initiatives and Growth Drivers:** The company's growth was bolstered by strong performance in chronic therapy segments and new product launches. Key highlights include the acquisition of Eli Lilly’s Huminsulin® and partnerships to commercialize NaMuscla® in Latin America.

**Business Developments:** Lupin received multiple regulatory approvals across geographies including the US FDA and EMA, enhancing its product pipeline. The company also successfully launched generic Pred Forte® in North America, capitalizing on exclusivity.

**Market Position and Competitive Advantage:** Lupin maintained its competitive edge with a diverse portfolio, ranking third in the U.S. generics market. The company’s strategic focus on complex generics and biosimilars is expected to provide significant growth opportunities.

**Investor Implications:** The impressive growth metrics and strategic partnerships bode well for investors, signaling a positive outlook for continued performance in the coming quarters. Potential risks include increased competition and regulatory challenges, warranting a close watch on market dynamics.